Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million ...

Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?

Wondering if Protagonist Therapeutics at about US$103.97 is still offering value, or if most of the opportunity is already reflected in the price. The stock has returned 5.5% over the past week, 1.0% ...

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA ...
Fierce Biotech

Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits

After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...

Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ ...
Den Of Geek

Tenet: Is the Protagonist the Real Villain?

This article contains Tenet spoilers. The Protagonist might be one of the most unimaginatively named main characters of all time, but it’s worth pointing out that he is referred to as “the Protagonist ...

Protagonist Therapeutics: Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible f ...